recurrent respiratory infections
Conditions
Interventions
18mg/kg co-trimoxazole (3mg trimethoprim + 15mg sulfamethoxazole) bid, until
the month of April (inclusive) or during 3 months, whichever is longer (to
prevent stopping the medication during the 'co
Sponsors
Jeroen Bosch Ziekenhuis
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: Children >6 months and 11 years). Definition of 'recurrent' respiratory infections: >=3 respiratory infections in the 6 months preceding study entry or start of the current therapy, or >=4 per year (documented by a doctor and treated with antibiotics).
Exclusion criteria
Exclusion criteria: - known primary immunodeficiency (e.g. CVID, a/hypogammaglobulinemia); - known secondary immunodeficiency (e.g. HIV, chemotherapy, transplantation); - eponymous syndromes; - chromosomal abnormalities; - cleft palate; - renal or hepatic insufficiency; - known glucose-6-phosphate deficiency, cystic fibrosis, primary ciliary dyskinesia or acute porphyria; - children using drugs known to interact with co-trimoxazole; - children with previous allergic reaction to co-trimoxazole.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection frequency per person month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life, emergence of antibiotic resistance in the commensal flora or in a disease-causing isolated bacterium, side effects, cost-effectiveness. | — |
Countries
Netherlands
Outcome results
None listed